Prostate Cancer

Among men with advanced prostate cancer, relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks.

The ATR inhibitor BAY 1895344 appeared promising in patients with a range of advanced, heavily pre-treated cancers in a dose-escalation portion of a phase 1 clinical trial.

TLX591-CDx (illumet) is a radiopharmaceutical targeting prostate-specific membrane antigen intended for the imaging of prostate cancer using positron emission tomography.

According to researchers, these early data support the rationale for further evaluation of immune-checkpoint inhibitor-based combinations in patients with metastatic castration resistant prostate cancer.

Treatment with a novel BiTE® immuno-oncology therapy showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

In patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss, ipatasertib combined with abiraterone acetate (Zytiga) plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity.

The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.

The study evaluated the use of darolutamide in men with nonmetastatic, castration-resistant prostate cancer compared with placebo while they continued to receive androgen-deprivation therapy.

Researchers indicated that these early data support the rationale for further evaluation of immune-checkpoint inhibitor-based combinations in patients with metastatic castration resistant prostate cancer.

This study found focal high intensity focused ultrasound ablation of the prostate to be safe and provide excellent potency, continence preservation, and adequate short-term prostate cancer control.

A phase 1b/2a study of the combination in patients with metastatic castration resistant prostate cancer demonstrated acceptable tolerability and potential efficacy.

CancerNetwork® spoke with Ahmet Murat Aydin, MD, about a study designed to evaluate bipolar radiofrequency ablation.

Researchers indicated that “these results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups.”

The findings supported the accelerated approval of rucaparib for the treatment of men with metastatic castration-resistant prostate cancer who have a deleterious BRCA mutation and who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.

This study found that implementation of the enhanced recovery after surgery pathway combined with prehabilitation programs can significantly change the postoperative course of patients.

In this study, investigators found that the hydrogel spacer has a favorable risk-benefit profile for patients receiving radiotherapy for prostate cancer.

This data may help to inform future recommendations for surveillance of BRCA1/2-associated cancers, according to researchers.

In this study, researchers observed no association between black race and the risk of SREs and overall mortality in men with bone metastatic castration-resistant prostate cancer.

Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.

The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.

Results showed that once daily relugolix established superiority over leuprolide and reduced the incidence of major cardiovascular events.

The study met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and whose tumors had PTEN loss.

Rencsok and colleagues found that the proportion of white participants in the clinical trials studied has primarily remained above 80% since 1990.

Researchers detailed methods and processes that may be useful for additional research and validation of computational hematoxylin and eosin staining deep learning models and the images generated by them.

Payment models with shared-savings components, such as the Oncology Care Model, may be associated with fewer visits and lower costs in certain cancer settings in the first year.

This study found that regional- and distant-stage prostate cancer incidence continues to increase in US men aged ≥50 years.

The FDA approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

A recent examination of older adults with cancer found accelerated losses in differing sarcopenia measures existed before and after a cancer diagnosis.

The FDA approved rucaparib for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.

The chairman of the Glickman Urological & Kidney Institute at the Cleveland Clinic provides commentary and an adjacent perspective to the Duke Cancer Institute report.